title: Galectin-1 and immunotherapy for brain cancer.
abstract: The prognosis of patients diagnosed with high-grade glioma continues to be dismal in spite of multimodal treatment. Active specific immunotherapy by means of dendritic cell vaccination is considered to be a new promising concept that aims at generating an anti-tumoral immune response. However, it is now widely accepted that the success of immunotherapeutic strategies to promote tumor regression will rely not only on enhancing the effector arm of the immune response but also on downregulation of the counteracting tolerogenic signals. In this article, we summarize evidence that galectin-1, an evolutionarily conserved glycan-binding protein that is abundantly expressed in high-grade glioma, is an important player in glioma-mediated immune escape.
authors.affiliation: Laboratory of Experimental Immunology, Catholic University Leuven, Leuven, Belgium.
authors.forename: Tina
authors.initials: T
authors.lastname: Verschuere
authors.forename: Steven
authors.initials: S
authors.lastname: De Vleeschouwer
authors.forename: Florence
authors.initials: F
authors.lastname: Lefranc
authors.forename: Robert
authors.initials: R
authors.lastname: Kiss
authors.forename: Stefaan W
authors.initials: SW
authors.lastname: Van Gool
mesh_terms: D001932:Brain Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003713:Dendritic Cells / Q000276:immunology*; D037483:Galectin 1 / Q000502:physiology*; D005910:Glioma / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D006801:Humans; D016233:Immunotherapy, Active; D019139:Tumor Escape
chemical_list: D019496:Cancer Vaccines; D037483:Galectin 1